Ricevi le ultime notizie sulle azioni ENDRA Life Sciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NDRA

Ultime notizie per

ENDRA LIFE SCIENCES INC

ENDRA Life Sciences

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

ENDRA Life Sciences Inc

Press Releases

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

News

MAG 7 Undercard: $5 Stocks to Watch – NDRA, BSLK, WOLF, OCC, SNYR Poised for Action More Inside

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

AMZN

BSLK

COST

NDRA

PNPNF

PRSO

SNYR

TSXV:PNPN

WOLF

Aethlon Medical

Autonomix Medical

Baird Medical Investment Holdings Ltd - Warrant

Baird Medical Investment

HeartBeam

Bluejay Diagnostics

Biomerica

Check-Cap

Envoy Medical

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Alpha Tau Medical

GlucoTrack

HeartSciences

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

INVO Fertility

Spectral AI

NanoVibronix

Nuwellis

Predictive Oncology

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Tenon Medical

Venus Concept

Catheter Precision

Ascendiant Capital

HC Wainwright & Co.

Comments

ENDRA Life Sciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO